10-Q: Seres Therapeutics Reports Q2 2025 Results, Faces Going Concern Doubt

Seres Therapeutics reported a net income for the first half of 2025 driven by the VOWST business sale, but faces substantial doubt about its ability to continue as a going concern without additional funding by Q1 2026.

Summary

• Reported a net income of $12.827 million for the six months ended June 30, 2025, compared to a net loss of $73.003 million for the same period in 2024.
• Operating loss for the six months ended June 30, 2025, was $52.117 million.
• Accumulated deficit as of June 30, 2025, stands at $965.272 million.
• Cash and cash equivalents totaled $45.379 million as of June 30, 2025.
• The company anticipates requiring additional funding in the first quarter of 2026.
• Substantial doubt exists regarding the company's ability to continue as a going concern for 12 months from the financial statement issuance date.
• The sale of the VOWST business to Nestlé Health Science (SPN) in September 2024 generated significant cash, including a $50 million installment received in January 2025 and a $25 million installment received on July 1, 2025.
• SER-155, an investigational oral live biotherapeutic, received Breakthrough Therapy designation from the FDA in December 2024 for reducing bacterial bloodstream infections (BSIs) in allo-HSCT patients.
• Phase 1b study results for SER-155 in allo-HSCT Cohort 2 showed a 77% relative risk reduction in bacterial BSIs and a significant reduction in systemic antibiotic exposure.
• Exploratory biomarker data for SER-155 showed lower fecal albumin and reduced systemic inflammatory responses, supporting its intended therapeutic mechanisms.
• A Phase 2 study protocol for SER-155 in allo-HSCT was filed with the FDA in May 2025, expected to enroll approximately 248 participants with an adaptive design and interim data analysis within 12 months of initiation.
• Research and development expenses decreased by $10.5 million to $24.760 million for the six months ended June 30, 2025, primarily due to lower headcount and completion of the SER-155 Phase 1b study.
• General and administrative expenses decreased by $5.9 million to $22.141 million for the six months ended June 30, 2025, due to reduced headcount and cost containment efforts.
• Manufacturing services expenses, related to the Transition Services Agreement (TSA) with Nestlé, were $5.2 million for the six months ended June 30, 2025.
• The company regained compliance with Nasdaq's $1.00 minimum bid price requirement in May 2025 following a 1-for-20 reverse stock split in April 2025.

Sentiment

Score: 4

Explanation: While the clinical data for SER-155 is highly positive and the Breakthrough Therapy designation is a significant achievement, the explicit 'going concern' warning and the immediate need for substantial additional funding by Q1 2026 overshadow these positives. The company's future is heavily reliant on securing this capital, which introduces significant uncertainty and risk, despite the strategic focus and promising pipeline.

Positives

• Achieved a net income of $12.827 million for the six months ended June 30, 2025, a significant improvement from a $73.003 million net loss in the prior year period.
• SER-155 received Breakthrough Therapy designation from the FDA in December 2024 for reducing bacterial bloodstream infections in allo-HSCT patients, potentially accelerating its development and review.
• Phase 1b study results for SER-155 demonstrated a 77% relative risk reduction in bacterial bloodstream infections and a significant reduction in systemic antibiotic exposure, indicating strong efficacy signals.
• Exploratory biomarker data for SER-155 supported its intended therapeutic mechanisms, including improved intestinal barrier integrity and reduced systemic inflammation.
• Regained compliance with Nasdaq's minimum bid price requirement in May 2025, mitigating immediate delisting concerns.
• The sale of the VOWST business provided substantial cash proceeds, including a $50 million installment in January 2025 and a $25 million installment in July 2025, improving the cash position to $45.379 million as of June 30, 2025.
• Reduced research and development expenses by $10.5 million and general and administrative expenses by $5.9 million for the six months ended June 30, 2025, reflecting cost containment and strategic focus.

Negatives

• Identified conditions and events that raise substantial doubt regarding the ability to continue as a going concern, requiring additional funding by Q1 2026.
• Despite net income, the company still has a significant accumulated deficit of $965.272 million as of June 30, 2025, and expects continued operating losses.
• The planned Phase 2 study of SER-155 requires additional capital to begin, posing a potential delay if funding is not secured.
• The total amount of future Milestone Payments from the VOWST Transaction is uncertain and contingent on sales targets, with accrued interest on the Prepaid Milestone reducing future payments.
• The company is now a smaller, less diversified entity following the VOWST sale, increasing susceptibility to market conditions and risks associated with early-stage development.
• Reliance on third parties for clinical trials and manufacturing introduces risks of delays, non-compliance, or insufficient supply.

Risks

• Will need additional funding in order to advance development of product candidates (including to complete the planned Phase 2 study of SER-155 in allo-HSCT) and commercialize product candidates, if approved. Inability to raise capital or secure a partnership could force delays, reductions, or elimination of product development programs or commercialization efforts.
• Identified conditions and events that raise substantial doubt regarding the ability to continue as a going concern.
• Is a clinical-stage company and has incurred significant losses since inception, expecting to incur losses for the foreseeable future and may never achieve or maintain profitability.
• The total amount of Milestone Payments from the VOWST Transaction, and amounts payable or due under Profit Sharing Payments, are subject to various risks and uncertainties.
• May not be able to realize the anticipated benefits of the VOWST Transaction, and may face new challenges as a smaller, less diversified company.
• Limited operating history may make it difficult to evaluate the success of the business to date and to assess future viability.
• Is early in development efforts of product candidates and may not be successful in efforts to use the reverse translational platform to build a pipeline of product candidates and develop additional marketable drugs.
• Product candidates are based on live biotherapeutics, which is a novel approach to therapeutic intervention, potentially leading to longer regulatory review processes.
• Clinical drug development involves a risky, lengthy and expensive process, with an uncertain outcome, potentially incurring additional costs or experiencing delays.
• Delays or difficulties in the enrollment of patients in clinical trials could result in receipt of necessary regulatory approvals being delayed or prevented.
• Disruptions at the FDA and other government agencies caused by funding shortages or staffing limitations could hinder their ability to hire, retain or deploy key personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all.
• Current and future legislation or regulation may increase the difficulty and cost to obtain marketing approval of and commercialize product candidates and may adversely affect prices.
• If not able to obtain, or if there are delays in obtaining, required regulatory approvals, will not be able to commercialize product candidates or will not be able to do so as soon as anticipated, materially impairing revenue generation.
• Relies, and expects to continue to rely, on third parties to conduct clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines.
• Even if any product candidates receive marketing approval, such product candidates may fail to achieve the degree of market acceptance by physicians, patients, hospitals, third-party payors and others in the medical community necessary for commercial success.
• Faces substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully.
• If unable to adequately protect proprietary technology or obtain and maintain issued patents sufficient to protect product candidates, others could compete more directly, having a material adverse impact.
• Future success depends on ability to manage recent CEO transition, to retain key executives and to attract, retain and motivate qualified personnel.
• Recent reverse stock split may not result in the market price per share of common stock to either exceed or remain in excess of the $1.00 minimum bid price as required by Nasdaq, or have any of its other anticipated impacts, and may be unable to satisfy or maintain other Nasdaq continued listing rules.

Future Outlook

The company anticipates requiring additional funding in the first quarter of 2026 to support ongoing operations and meet obligations. Management plans to secure capital through financing or other strategic transactions, including potential business development deals and selling shares via its at-the-market equity offering. The company expects operating losses and negative cash flows to continue for the foreseeable future, despite a net income for the first half of 2025. Future expenses are expected to increase with continued clinical development of SER-155 and other pipeline candidates, strategic investments in manufacturing, and intellectual property maintenance. The company is actively discussing various deal structures, including partnerships, out-licensing, and mergers, to enable clinical progression of SER-155 and advance its pipeline. The SER-155 Phase 2 study is expected to enroll approximately 248 participants, with interim clinical results anticipated within twelve months of study initiation, which could facilitate timely engagement with the FDA on Phase 3 design and inform development in adjacent patient populations. Positive Phase 2 results could enable advancement into a single Phase 3 trial for registration. The company is also exploring options, including potential partnerships, to advance biotherapeutics in inflammatory and immune diseases like ulcerative colitis and Crohn's disease.

Management Comments

• "We are progressing the development of SER-155, an investigational, oral, live biotherapeutic designed to decolonize gastrointestinal, or GI, pathogens, improve GI epithelial barrier integrity, and induce immune homeostasis to prevent bacterial bloodstream infections, or BSIs, including those that can harbor antimicrobial resistance, or AMR, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation, or allo-HSCT."
• "Based on prior FDA feedback, we have continued preparations for a SER-155 Phase 2 study in allo-HSCT that could provide a time and capital-efficient path to obtaining clinical results. We require additional capital to begin this study."
• "We are in active discussions with multiple parties regarding sources of capital and other resources as we execute on our strategy to advance SER-155 and our broader portfolio of live biotherapeutic product candidates."
• "Ongoing discussions are addressing various deal structures, including partnerships, out-licensing deals, mergers and other types of transactions with counterparties who could provide capital and other resources to enable the clinical progression of SER-155 and continue advancement of our pipeline."
• "We believe that SER-155 and other cultivated live biotherapeutic candidates could be developed in additional patient populations beyond allo-HSCT, including autologous-HSCT patients, cancer patients with neutropenia, chimeric antigen receptors therapy recipients, or CAR-T, individuals with chronic liver disease, or CLD, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities."
• "We are exploring options, including potential partnerships, to advance the development of our biotherapeutics in inflammatory and immune diseases, including ulcerative colitis and Crohn's disease."
• "Based on our currently available cash resources, including the capital obtained from the Transaction, and considering our future operating plans and our ongoing obligations related to the Transaction, we anticipate that we will require additional funding in the first quarter of 2026."
• "Management has concluded that substantial doubt exists about our ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued."

Industry Context

The company operates in the highly competitive and rapidly evolving biotechnology industry, specifically focusing on novel live biotherapeutics. The successful FDA approval of VOWST (now sold) and the Breakthrough Therapy designation for SER-155 highlight the growing recognition and potential of microbiome-based therapies. The industry faces challenges such as lengthy and expensive clinical development, high competition from major pharmaceutical and biotech companies, and increasing scrutiny over drug pricing and reimbursement. The focus on antimicrobial resistance (AMR) with SER-155 aligns with global public health priorities, as AMR is a top ten global health threat. The trend towards strategic partnerships and capital raises is common for clinical-stage biotechs to fund extensive R&D and navigate regulatory pathways.

Comparison to Industry Standards

• The 77% relative risk reduction in bacterial BSIs for SER-155 in allo-HSCT patients is a strong efficacy signal, comparable to or exceeding efficacy seen in some early-stage trials for novel anti-infectives or microbiome modulators in vulnerable populations. For example, other companies developing microbiome therapies for infection prevention, such as those targeting C. difficile recurrence (e.g., Rebiotix's RBX2660, now Ferring's Rebyota), have shown significant reductions in recurrence rates, validating the potential of this therapeutic approach.
• The FDA's Breakthrough Therapy designation for SER-155 indicates that preliminary clinical evidence suggests substantial improvement over existing therapies, placing it in a select group of promising drug candidates. This designation is a strong positive signal, similar to how other companies like Vertex Pharmaceuticals have leveraged such designations to accelerate development for cystic fibrosis therapies.
• The company's accumulated deficit of $965.3 million and the need for additional funding by Q1 2026 are common for clinical-stage biotechnology companies, which typically incur significant R&D expenses for many years before potential profitability. This financial profile is similar to many early-to-mid stage biotechs that rely on capital raises and partnerships to advance their pipelines, such as smaller oncology or rare disease focused biotechs before a major drug approval.
• The strategic decision to sell the VOWST business to Nestlé Health Science, while providing immediate capital, also reduced the company's diversification. This is a common strategy in the biotech sector where companies may divest non-core assets to focus on lead candidates, similar to how some smaller biotechs might out-license regional rights or specific indications to larger pharmaceutical partners to fund their primary development programs.

Management Changes

Corporate Governance

Legal Proceedings

• On August 20, 2024, Vedanta Biosciences, Inc. and The University of Tokyo filed a complaint against the company and Nestlé entities in the U.S. District Court for the District of Delaware, alleging infringement of five U.S. patents related to the making, sale, and use of VOWST. The complaint seeks unspecified damages, fees, expenses, and injunctive relief. The company believes the complaint is without merit and intends to defend vigorously.

Related Party Transactions

• Sale of VOWST Business to Socit des Produits Nestl S.A. (SPN), a wholly-owned subsidiary of Nestlé S.A., completed on September 30, 2024.
• Received a $50 million cash installment payment from SPN on January 15, 2025, and a $25 million installment on July 1, 2025 (offset by $1.421 million paid to Nestlé for employment obligations).
• Future milestone payments of $125 million (for $400 million net sales) and $150 million (for $750 million net sales) are contingent on VOWST sales targets, with interest accruing on a $60 million prepaid milestone.
• Entered into a Transition Services Agreement (TSA) with NESA (an SPN affiliate) to provide manufacturing and administrative services until December 31, 2025, with NESA reimbursing certain fixed and variable costs.
• Recognized $3.490 million and $9.799 million of TSA reimbursement income for the three and six months ended June 30, 2025, respectively.
• Incurred $1.689 million and $5.216 million in manufacturing services expenses and $1.261 million and $3.509 million in TSA labor and passthrough expenses for the three and six months ended June 30, 2025, respectively.
• As of June 30, 2025, had $882,000 in accounts receivable due from SPN and $279,000 unbilled receivable related to transition services.
• Accrued liabilities due to SPN related party totaled $13.453 million as of June 30, 2025, including $8.008 million for Profit Sharing Payments, $2.788 million for MSK Agreement royalties, $356,000 for VOWST post-marketing safety study, $880,000 for Waltham facility lease costs, and $1.421 million for employment-related costs.
• SPN purchased 714,285 shares of common stock for $15 million at $21.00 per share at Closing, and SPN designated Hans-Juergen Woerle, M.D., Ph.D. to the Board as a Class III director.
• Entered into a cross-license agreement with SPN, granting SPN exclusive (for 5 years) and then co-exclusive rights to certain patents and know-how in the CDI field, and SPN granted the company non-exclusive rights for products outside the CDI field.

Stakeholder Impact

• **Shareholders**: Face substantial dilution risk from potential future equity raises. The 'going concern' warning creates significant uncertainty and could negatively impact share price. The VOWST sale provided cash but reduced the company's asset base and diversification. The patent infringement lawsuit related to VOWST could lead to liabilities.
• **Employees**: Experienced a headcount reduction of approximately 100 employees due to the VOWST business sale. Management changes, including the CEO transition, could impact morale and stability. The company's ability to attract and retain qualified personnel is critical for future success, especially given intense competition in the biotech sector.
• **Customers (future)**: Potential patients for SER-155 (allo-HSCT patients) could benefit from a novel therapeutic for bacterial bloodstream infections, especially given the Breakthrough Therapy designation. However, delays in clinical trials due to funding issues could impact product availability.
• **Suppliers/Creditors**: The 'going concern' doubt may make it more difficult for the company to obtain financing or engage with new collaborators/suppliers on favorable terms, as they may be concerned about the company's ability to meet contractual obligations.
• **Regulatory Authorities**: The company's compliance with FDA and other regulatory requirements is under continuous scrutiny, with potential for fines or delays if non-compliance occurs. The novel nature of live biotherapeutics may lead to longer or more complex regulatory reviews.

Next Steps

• Secure additional funding through financing or strategic transactions by Q1 2026.
• Finalize and initiate the SER-155 Phase 2 study in allo-HSCT, expected to enroll approximately 248 participants.
• Obtain interim clinical results from the SER-155 Phase 2 study within twelve months following study initiation.
• Engage with the FDA on the design of a Phase 3 study for SER-155 based on Phase 2 interim results.
• Explore development of SER-155 in adjacent medically vulnerable patient populations (e.g., autologous-HSCT, cancer patients with neutropenia, CAR-T recipients, chronic liver disease, solid organ transplant recipients, ICU/long-term acute care patients).
• Continue IND-enabling activities for SER-147.
• Explore options, including potential partnerships, to advance the development of biotherapeutics in inflammatory and immune diseases (e.g., ulcerative colitis, Crohn's disease).
• Continue to provide manufacturing and other transition services to NESA under the TSA until December 31, 2025.

Key Dates

Recommendation

The filing presents a mixed bag of strong clinical progress and significant financial challenges. The Breakthrough Therapy designation for SER-155 and its promising Phase 1b data are clear positives, indicating potential for a valuable therapeutic. However, the explicit 'going concern' warning and the immediate need for additional capital by Q1 2026 introduce substantial financial risk. While the VOWST sale provided a cash infusion, it's not sufficient for long-term operations, and future milestone payments are uncertain. The management transition adds another layer of uncertainty. For a seasoned investor, the potential upside from SER-155 is attractive, but the near-term funding risk is paramount. A 'hold' recommendation is appropriate, acknowledging the promising pipeline while emphasizing the critical need for successful capital raise and the inherent risks of a clinical-stage biotech with going concern issues. Investors should await clarity on the funding situation and further clinical milestones before considering a 'buy' or 'sell' position.

Keywords

Biotechnology, Live Biotherapeutics, SER-155, Allogeneic Hematopoietic Stem Cell Transplantation, Bacterial Bloodstream Infections, Antimicrobial Resistance, Clinical Stage, FDA Breakthrough Therapy, Orphan Drug, SEC Filing, 10-Q, Financial Health, Corporate Governance, Risk Management, Drug Development, Clinical Trials, Biopharmaceutical, Microbiome, VOWST